With lung cancer as the leading cause of cancer-related death worldwide and with the risk of complications from invasive surgeries, there is a need for minimally invasive ablative therapies for the treatment of lung tumours. It was a pleasure to talk with Dr. Daniel Steinfort (Royal Melbourne Hospital, Melbourne, Australia) to learn more around the need for minimally invasive therapies in the treatment of lung tumours, the advantages of using an externally cooled bronchoscopic radiofrequency ablation catheter and the findings from the first-in-human dose escalation study of this catheter.
The abstract ‘Safety and feasibility of a novel externally cooled bronchoscopic radiofrequency ablation catheter for ablation of peripheral lung tumours: a first-in-human dose escalation study.‘ (Abstract number: OA2269) was presented at ERS 2022, 4–6 September, 2022.
Questions
- Why are minimally invasive therapies needed in the treatment of early stage peripheral lung tumours? (0:29)
- Could you tell us a little about the externally cooled bronchoscopic radiofrequency ablation catheter and its potential advantages? (1:24)
- What preclinical evidence supports the use of this catheter? (3:27)
- Could you give us an overview of the first-in-human dose escalation study and its findings? (4:17)
- What will be the next step in the clinical development of the externally cooled bronchoscopic radiofrequency ablation catheter? (6:43)
Disclosures: Daniel Steinfort discloses receiving grant/ research support from NHMRC; honoraria from Astra Zeneca and Broncus Medical; and study funds from Zidan Medical (no individual reimbursement).
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
